SEC Filings
Revvity Targets Above-Market Growth And $5 Billion For Deals, Buybacks And Dividends
The research-tools and diagnostics company pairs its growth ambitions with margin targets after cutting staff and facilities space.
Revvity (RVTY) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The research-tools and diagnostics company pairs its growth ambitions with margin targets after cutting staff and facilities space.
Earnings
The lab-science company posted third-quarter revenue of $729 million and now sees full-year adjusted earnings of $5.40-$5.45 a share.
Earnings
Revvity guides fourth-quarter organic growth to about 5%, down from 7% in the third, as its CEO calls AI demand "very early days."